MedTrace Logo

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

NCT07051707 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-28

No results posted yet for this study

Summary

The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.

Conditions

Interventions

DEVICE

Targeted Lung Denervation (TLD)

Targeted Lung Denervation (TLD)Therapy is a bronchoscopically guided minimally invasive one-time treatment using the dNerva Lung Denervation System.

Sponsors & Collaborators

  • Temple Health

    collaborator UNKNOWN

  • Nuvaira, Inc.

    lead INDUSTRY

Principal Investigators

  • Prof. Gerard Criner, MD · Temple Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-24
Primary Completion
2028-04-30
Completion
2029-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07051707 on ClinicalTrials.gov